Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2003 Aug 4;198(3):455–467. doi: 10.1084/jem.20010897

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2003, The Rockefeller University Press

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 4. — Comparison of the viability of peripheral blood eosinophils with BALF eosinophils after stimulation with neurotrophins. Isolated eosinophils (0.5 × 10⁵/ml) of peripheral blood (PB-Eos) from healthy subjects (A, n = 6) or asthmatics 10 min before (B, n = 4) and 18 h after SAP (C, n = 4) as well as BALF eosinophils collected 18 h after SAP (BALF-Eos; D, n = 4) were incubated with 50 ng/ml NGF, BDNF, NT-3, or NT-4, respectively, or with 10 ng/ml IL-5 or cell culture medium alone (control). The viability was assessed by flow cytometry with PI immediately after isolation (0 d) and after 1, 2, and 3 d (PB-Eos from healthy subjects) or after 3, 5, and 7 d (PB-Eos from asthmatics before and after SAP) or after 0, 3, 5, 7, 10, and 14 d, respectively (BALF-Eos from asthmatics); * significant differences (P < 0.05).